prostate cancer

[RhoVac AB (PR Newswire, LLC)] RhoVac AB announced that its Safety Monitoring Committee has conducted a planned interim safety review of its clinical Phase IIb trial in prostate cancer, known as BRaVac.

[PLoS One] Researchers investigated whether miR-196a played a role in the regulation of the β2-adrenergic receptor in the LNCaP prostate cancer cell line.

[Clinical Laserthermia Systems AB] Clinical Laserthermia Systems AB announced that its collaboration with Otto-von-Guericke-University Magdeburg, Medical faculty has obtained approval from the ethics committee, and from the responsible Competent Authority, in Germany. CLS and the Magdeburg medical team will now proceed with Investigator Initiated Trial regarding MRI-Ultrasound, fusion-guided focal laser ablation treatment of prostate cancer.

[Nature Reviews Urology] CAR T cell therapy has the potential to be combined with other treatment modalities, such as androgen deprivation therapy, radiotherapy or chemotherapy, and could be applied as focal CAR T cell therapy for prostate cancer.

[Nature Communications] In both ERG positive VCaP cells and ERG/PTEN mice, PTEN loss results in AKT activation and EZH2 phosphorylation at serine 21 that favors ERG methylation.

[Gene Therapy] The authors found that miR-34a overexpression significantly inhibited the cell cycle, viability, and migration of prostate cancer cells by targeting its downstream genes.